SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dr. Reddy’s Laboratories launches Metaxalone Tablets in US market

06 Sep 2017 Evaluate

Dr. Reddy’s Laboratories has launched Metaxalone Tablets, USP 800 mg, a therapeutic equivalent generic version of Skelaxin (metaxalone) Tablets, approved by the U.S. Food and Drug Administration (USFDA).

The Skelaxin brand and generic had U.S. sales of approximately $139 million MAT for the most recent twelve months ending in July 2017 according to IMS Health. The company’s Metaxalone Tablets, USP 800 mg are available in the bottle count size of 100. Skelaxin is a trademark of King Pharmaceuticals Research and Development, Inc.

Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Lab Share Price

1282.15 -11.10 (-0.86%)
11-May-2026 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1872.40
Dr. Reddys Lab 1282.15
Cipla 1304.70
Zydus Lifesciences 956.65
Lupin 2249.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×